RESUMO
Acne fulminans (AF) is a rare, serious, sudden-onset and long-lasting skin disease that causes scarring of face and body. Standard treatment with combined long-term isotretinoin and prednisolone is not always sufficient and has a well-known propensity for adverse effects leaving an unmet need for improved therapy. Case reports suggest that tumor necrosis factor (TNF)-α inhibitors may play a role in the management of AF. In a 3-year retrospective data collection from two dermatology centers and literature review of clinical cases of acne fulminans treated with anti-TNF-α therapy, three clinical cases and twelve literature cases were identified. A total of five different TNF-α inhibitors have been tested, with adalimumab being the most commonly used. Clinical response was seen after 1 month in 2/3 (67%) clinical cases and 5/12 (42%) literature cases, respectively, and treatment was successful in 2/3 (67%) and 11/12 (92%) after a median 3-7 months. All reported adverse effects were mild and reversible. Anti-TNF-α treatment may provide rapid improvement in patients with AF when initial treatment with isotretinoin and prednisolone fails. However, randomized controlled trials are lacking, and exact dosage and timing need to be explored before clinical implementation.
Assuntos
Acne Vulgar , Fármacos Dermatológicos , Humanos , Isotretinoína/uso terapêutico , Isotretinoína/efeitos adversos , Fator de Necrose Tumoral alfa , Estudos Retrospectivos , Inibidores do Fator de Necrose Tumoral , Acne Vulgar/patologia , Prednisolona/uso terapêuticoRESUMO
BACKGROUND: Rosacea is a common chronic inflammatory facial skin disorder. Standardized evaluation of the severity and extent of rosacea is important for baseline assessment and treatment effect. The currently used Investigator's Global Assessment (IGA) is unspecific and fails to consider subtypes/phenotypes of rosacea and area involvement. The Rosacea Area and Severity Index (RASI) was developed to give a more nuanced evaluation of rosacea features in four facial skin areas adjusted to the relative importance of each area of the face to obtain an overall severity score. OBJECTIVES: To validate RASI against the IGA and to assess the inter- and intraobserver reliability for RASI. METHODS: Sixteen dermatologists evaluated photographs of 60 adult patients with rosacea (3 photographs per patient, one from the front and one from each side). IGA and RASI scores were performed for interobserver reliability assessment. To determine intraobserver reliability, 14 dermatologists evaluated 10 other patients twice with at least 1 week interval. RESULTS: The IGA and RASI correlated well (Spearman correlation coefficient (SCC) = 0.75, 95% confidence interval (CI) = 0.72-0.78). Interobserver reliability was moderate for RASI and poor to moderate for IGA. Reliability was strongest for rhinophyma, followed by papules/pustules and erythema, and rather weak for telangiectasia. For area scores, interobserver reliability was strongest for cheeks, followed by nose, chin and forehead. We found a moderate-to-strong intraobserver agreement both for IGA and RASI. CONCLUSIONS: We have designed a new practical tool to examine clinical severity of rosacea. RASI proved simple and reliable in scoring clinical severity of rosacea with an agreement comparable to the currently used IGA although RASI will provide a more nuanced view of the current rosacea extent and severity. We suggest that RASI is used in the daily clinical setting as well as in clinical studies assessing the efficacy of rosacea therapies.
Assuntos
Rosácea , Humanos , Reprodutibilidade dos Testes , Rosácea/diagnóstico , Rosácea/tratamento farmacológico , Pele , Eritema , Imunoglobulina A , Índice de Gravidade de DoençaRESUMO
Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin-4 and interleukin-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis treated off-label with dupilumab, and a review of the existing literature. All patients in this study had longstanding severe disease and had tried multiple treatment modalities. They were treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. Systematic literature searches were performed to identify literature describing the evaluation of the effect of treatment with dupilumab in prurigo nodularis. The physician's assessment of the patients revealed a good or excellent response to the treatment with dupilumab. Patients were evaluated after treatment for 4 and 7 months. Treatment was generally well-tolerated; one in three patients reported dry eyes. Four studies with a total of 11 patients (range: 1-4) were identified by the literature search. Complete response was noted in all 11 patients. Treatment with dupilumab appears to be safe and well-tolerated with clinical benefit in recalcitrant prurigo nodularis. Larger randomized and controlled trials using validated outcome measures are needed before dupilumab could be applied in clinical settings.
Assuntos
Prurigo , Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais Humanizados , Humanos , Interleucina-13 , Prurigo/diagnóstico , Prurigo/tratamento farmacológico , Resultado do TratamentoRESUMO
Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults. We present a case of a 7-year-old boy with infection-associated TEN, diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae. Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.
Assuntos
Fármacos Dermatológicos/uso terapêutico , Infliximab/uso terapêutico , Síndrome de Stevens-Johnson/tratamento farmacológico , Criança , Humanos , Masculino , Mycoplasma pneumoniae/isolamento & purificação , Síndrome de Stevens-Johnson/microbiologia , Síndrome de Stevens-Johnson/patologiaAssuntos
Medicamentos Biossimilares/administração & dosagem , Etanercepte/administração & dosagem , Infliximab/administração & dosagem , Psoríase/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Antirreumáticos/administração & dosagem , Antirreumáticos/efeitos adversos , Medicamentos Biossimilares/efeitos adversos , Etanercepte/efeitos adversos , Feminino , Humanos , Infliximab/efeitos adversos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do TratamentoRESUMO
Omalizumab is a recombinant humanized monoclonal antibody targeting the high-affinity Fc receptor of IgE, registered for the treatment of chronic spontaneous urticaria and severe allergic asthma. We present a case series of nine patients with atopic dermatitis (AD) treated off-label with omalizumab and a systematic review of the existing literature. Patients were selected consecutively from a tertiary dermatological referral center during a 5-year period. All patients were treated with omalizumab at a starting dose of 300 mg subcutaneously every 4 weeks. Systematic literature searches were performed in PubMed, Web of Science, EMBASE, and ClinicalTrials.gov to identify any study (case reports, case series, and controlled trials) evaluating the effect of treatment with omalizumab in AD. Based on physicians' assessment, 50% of our patients had a good or excellent response to treatment with omalizumab; a further 12.5% had a moderate response, while 37.5% experienced no response or deterioration of symptoms during treatment. Treatment was generally well tolerated. Twenty-six studies with a median of four patients each (range 1-21), comprising 174 patients, were included in the systematic review. Summed over all studies, a total of 129 patients (74.1%) experienced a beneficial effect of treatment ranging from little to complete response. Omalizumab appears to be a safe and well tolerated, however expensive, treatment with some clinical benefit in patients with severe recalcitrant AD. Recommendation for use in clinical practice awaits evidence from larger randomized controlled trials.
Assuntos
Antialérgicos/uso terapêutico , Dermatite Atópica/tratamento farmacológico , Omalizumab/uso terapêutico , Adulto , Idoso , Antialérgicos/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Uso Off-Label , Omalizumab/efeitos adversos , Resultado do Tratamento , Adulto JovemRESUMO
Topical 8% capsaicin is a recently approved treatment for post-herpetic neuralgia (PHN). Capsaicin works by causing extensive depolarization of nociceptive epidermal transient receptor potential cation channel V1-positive C-fibers leading to defunctionalization. In this case story a 51-year-old male patient, who was suffering from severe PHN pain and associated allodynia, experienced drastic pain relief upon treatment with topical 8% capsaicin. Pain associated with the patch application could be successfully alleviated by pretreatment with topical lidocaine/prilocaine 2.5% and/or oral tramadol. Topical 8% capsaicin should be considered as a feasible treatment option for PHN.
Assuntos
Capsaicina/administração & dosagem , Neuralgia Pós-Herpética/tratamento farmacológico , Fármacos do Sistema Sensorial/administração & dosagem , Capsaicina/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Medição da Dor , Fármacos do Sistema Sensorial/farmacologia , Adesivo TransdérmicoRESUMO
Notalgia paresthetica (NP) is a focal neuropathic itch condition manifesting in intense chronic or recurrent episodic itch in a hyperpigmented, macular, uni- or bilateral skin area located below and/or medially to the scapulae. Achieving satisfactory relieve in NP patients is challenging. In this case-series three female NP patients were treated with 8% capsaicin patches following a spatial quantification of their alloknetic area with a von Frey filament. The use of a von Frey filament in order to delimit the precise area of itch sensitization and thus patch application, proved clinically feasible. Although 8% topical capsaicin relieved itch in all three patients, the duration of the effectiveness varied greatly from only 3 days to >2 months. The treatment was well tolerated in the patients and there appear to be no significant hindrances to applying this treatment with NP as an indication, although it may only exhibit satisfactory effectiveness in certain patients. Placebo-controlled double-blinded trials are needed to confirm the effectiveness of the treatment and assess predictive parameters of the treatment outcome.
RESUMO
BACKGROUND: Reducing the number of doses in the human papillomavirus (HPV) vaccination regimen from 3 to 2 could increase coverage rates. In this cohort study, we assessed the risk of genital warts (GWs) according to timing and number of doses of quadrivalent HPV vaccine. METHODS: From population-based registries, we identified all girls in Denmark born during 1985-1999, for whom information on HPV vaccinations was retrieved. The cohort was followed for GW occurrence during 2006-2012. Incidence rate ratios (IRRs) were calculated by Poisson regression to determine differences in GW rates by number of vaccine doses. RESULTS: Of the 550,690 girls in the cohort, 361 734 had been vaccinated. Of these, 25.9% had been vaccinated twice and 58.8% 3 times. The risk of GWs decreased significantly with each additional dose of vaccine. For girls who received 2 doses, extension of the interval between doses reduced the incidence of GWs. In comparison with a 2-month interval, the incidence of GWs was reduced by 45% (95% confidence interval [CI], 20%-62%), 55% (95% CI, 35%-69%), and 63% (95% CI, 44%-75%), with an interval of 4, 5, and 6 months, respectively. The IRR of 2 vs 3 doses was close to 1, with an interval of about 6 months between the first 2 doses. CONCLUSIONS: With the original vaccine schedule, completion of 3 doses seems to be required to obtain full protection against GWs. A 2-dose regimen may be as effective if the dosing interval is extended to around 6 months, although the long-term effectiveness of this regimen is unknown.
Assuntos
Condiloma Acuminado/epidemiologia , Condiloma Acuminado/prevenção & controle , Vacinas contra Papillomavirus/administração & dosagem , Vacinas contra Papillomavirus/imunologia , Adolescente , Adulto , Estudos de Coortes , Dinamarca/epidemiologia , Relação Dose-Resposta Imunológica , Feminino , Humanos , Vacinação em Massa/estatística & dados numéricos , Adulto JovemRESUMO
Risk of human papillomavirus (HPV) transmission during laser vaporisation of genital warts or loop electrode excision procedure is controversial. An oral rinse, a nasal swabs, history of HPV related diseases and data on HPV exposure were collected from 287 employees at departments of dermato-venerology and gynaecology in Denmark. A mucosal HPV type was found among 5.8% of employees with experience of laser treatment of genital warts as compared to 1.7% of those with no experience (p = 0.12). HPV prevalence was not higher in employees participating in electrosurgical treatment or cryotherapy of genital warts, or loop electrode excision procedure compared with those who did not. HPV 6 or 11 were not detected in any samples. Hand warts after the age of 24 years was more common among dermatology than among non-dermatology personnel (18% vs. 8.0%, p = 0.03). Mucosal HPV types are infrequent in the oral and nasal cavity of health care personnel, however, employees at departments of dermato-venereology are at risk of acquiring hand warts.
Assuntos
Condiloma Acuminado/cirurgia , Eletrocirurgia , Terapia a Laser/instrumentação , Lasers de Gás/uso terapêutico , Doenças da Boca/epidemiologia , Doenças Nasais/epidemiologia , Saúde Ocupacional , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/transmissão , Displasia do Colo do Útero/cirurgia , Condiloma Acuminado/virologia , Dinamarca , Eletrocirurgia/efeitos adversos , Feminino , Testes de DNA para Papilomavírus Humano , Humanos , Transmissão de Doença Infecciosa do Paciente para o Profissional , Terapia a Laser/efeitos adversos , Doenças da Boca/diagnóstico , Doenças da Boca/virologia , Mucosa Bucal/virologia , Mucosa Nasal/virologia , Doenças Nasais/diagnóstico , Doenças Nasais/virologia , Exposição Ocupacional , Infecções por Papillomavirus/diagnóstico , Infecções por Papillomavirus/virologia , Prevalência , Medição de Risco , Fatores de Risco , Displasia do Colo do Útero/virologiaRESUMO
ß3-Adrenoceptor agonists have recently been introduced for the treatment of overactive urinary bladder syndrome. Their target, the ß3-adrenoceptor, was discovered much later than ß1- and ß2-adrenoceptors and exhibits unique properties which make extrapolation of findings from the other two subtypes difficult and the ß3-adrenoceptor a less-understood subtype. This article discusses three aspects of ß3-adrenoceptor pharmacology. First, the ligand-recognition profile of ß3-adrenoceptors differs considerably from that of the other two subtypes, i.e., many antagonists considered as nonselective actually are ß3-sparing, including propranolol or nadolol. Many agonists and antagonists classically considered as being ß3-selective actually are not, including BRL 37,344 ((±)-(R*,R*)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy] acetic acid sodium hydrate) or SR 59,230 (3-(2-ethylphenoxy)-[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol oxalate). Moreover, the binding pocket apparently differs between the human and rodent ß3-adrenoceptor, yielding considerable species differences in potency. Second, the expression pattern of ß3-adrenoceptors is more restricted than that of other subtypes, particularly in humans; this makes extrapolation of rodent findings to the human situation difficult, but it may result in a smaller potential for side effects. The role of ß3-adrenoceptor gene polymorphisms has insufficiently been explored and may differ even between primate species. Third, ß3-adrenoceptors lack the phosphorylation sites involved in agonist-induced desensitization of the other two subtypes. Thus, they exhibit downregulation and/or desensitization in some, but not other, cell types and tissues. When desensitization occurs, it most often is at the level of mRNA or signaling molecule expression. All three of these factors have implications for future studies to better understand the ß3-adrenoceptor as a novel pharmacological target.
Assuntos
Agonistas de Receptores Adrenérgicos beta 3/farmacologia , Antagonistas de Receptores Adrenérgicos beta 3/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Receptores Adrenérgicos beta 3/genética , Receptores Adrenérgicos beta 3/metabolismo , Animais , Sítios de Ligação/genética , Regulação da Expressão Gênica/genética , Humanos , Ligantes , Polimorfismo Genético/genéticaRESUMO
Several receptor systems in the bladder causing detrusor smooth muscle contraction stimulate phospholipase C (PLC). PLC inhibition abolishes bladder contraction via P2Y6 but not that via M3 muscarinic receptors, indicating a receptor-dependent role of PLC. Therefore, we explored the role of PLC in rat bladder contraction by bradykinin. The PLC inhibitor U 73,122 [1-(6-[([17ß]-3-methoxyestra-1,3,5[10]-trien-17-yl)-amino]hexyl)-1H-pyrrole-2,5-dione] did not affect the bradykinin response to a significantly greater degree than its inactive analog U 73,343 [10 µM each; 1-(6-[-([17ß]-3-methoxyestra-1,3,5[10]-trien-17-yl)-amino]hexyl)-2,5-pyrrolidinedione], whereas the phospholipase D inhibitor butan-1-ol relative to its inactive control butan-2-ol caused a weak but significant inhibition (0.3% each). The cytosolic phospholipase A2 inhibitor arachidonyltrifluoromethyl ketone (300 µM) and the cyclooxygenase inhibitor indomethacin (10 µM) caused strong inhibition of the bradykinin response. The L-type Ca(2+) channel blocker nifedipine (10-100 nM) concentration-dependently caused strong inhibition, whereas only a small but significant inhibition was seen with SK&F 96,365 [10 µM; 1-[ß-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole HCl], an inhibitor of receptor-operated Ca(2+) channels. Several protein kinase C inhibitors yielded an equivocal picture (inhibition by 10 µM bisindolylmaleimide I and 1 µM calphostin but not by 10 µM chelerythrine). The rho kinase inhibitor Y 27,632 [1-10 µM; trans-4-[(1R)-1-aminoethyl]-N-4-pyridinylcyclohexanecarboxamide] caused a strong and concentration-dependent inhibition of the bradykinin response. Our data support that not only M3 but also bradykinin receptors cause bladder contraction by a largely PLC-independent mechanism. Both responses strongly involve L-type Ca(2+) channels and rho kinase, whereas only the bradykinin response additionally involves the phospholipase A2/cyclooxygenase pathway.
Assuntos
Bradicinina/fisiologia , Contração Muscular/fisiologia , Músculo Liso/enzimologia , Fosfolipases Tipo C/fisiologia , Bexiga Urinária/enzimologia , Animais , Bradicinina/farmacologia , Relação Dose-Resposta a Droga , Masculino , Contração Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Técnicas de Cultura de Órgãos , Ratos , Ratos Wistar , Fosfolipases Tipo C/antagonistas & inibidores , Bexiga Urinária/efeitos dos fármacosRESUMO
Genital warts are caused by human papillomavirus (HPV). HPV is a leading cause of anogenital malignancies and a role of HPV in the aetiology of oro-pharyngeal cancers has been demonstrated. The frequency of oral HPV infection in patients with genital warts and the association between concomitant genital, anal and oral infection is unclear. A total of 201 men and women with genital wart-like lesions were recruited. Swab samples were obtained from the genital warts and the anal canal and an oral rinse was collected. Anal HPV was found in 46.2% and oral HPV in 10.4% of the participants. Concordance between anal and genital wart HPV types was 78.1%, while concordance between oral and genital wart types was 60.9%. A lower concordance of 21.7% was observed between anal and oral HPV types. Significantly more women than men had multiple HPV types and anal HPV. In conclusion, extra genital HPV is common in patients with genital warts. A gender inequality seems to exist.
Assuntos
Canal Anal/virologia , Condiloma Acuminado/virologia , Boca/virologia , Papillomaviridae/isolamento & purificação , Infecções por Papillomavirus/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Condiloma Acuminado/epidemiologia , DNA Viral/isolamento & purificação , Dinamarca/epidemiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Papillomaviridae/genética , Prevalência , Reação em Cadeia da Polimerase em Tempo Real , Fatores Sexuais , Comportamento Sexual , Adulto JovemRESUMO
Human papillomavirus (HPV) is a highly prevalent sexually transmitted infection. High-risk HPV causes penile cancer and a substantial proportion of oropharyngeal and anal malignancy in men. Low-risk types of HPV cause anogenital warts. The incidence of oropharyngeal and anal cancers is increasing in Denmark. Prevention of penile, anal and oropharyngeal cancers and anogenital warts represents potential benefits of the HPV vaccine; and vaccination of men is now recommended by the Australian and the North American health authorities. Thus, we recommend that the Danish HPV vaccination program should include men.
Assuntos
Infecções por Papillomavirus/complicações , Adolescente , Neoplasias do Ânus/epidemiologia , Neoplasias do Ânus/prevenção & controle , Neoplasias do Ânus/virologia , Tumor de Buschke-Lowenstein/patologia , Condiloma Acuminado/epidemiologia , Condiloma Acuminado/prevenção & controle , Condiloma Acuminado/virologia , Efeitos Psicossociais da Doença , Dinamarca/epidemiologia , Feminino , Homossexualidade Masculina , Humanos , Programas de Imunização , Masculino , Neoplasias Orofaríngeas/epidemiologia , Neoplasias Orofaríngeas/prevenção & controle , Neoplasias Orofaríngeas/virologia , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus , Neoplasias Penianas/epidemiologia , Neoplasias Penianas/patologia , Neoplasias Penianas/prevenção & controle , Neoplasias Penianas/virologia , Adulto JovemRESUMO
BACKGROUND: Approximately 90% of genital warts (GWs) are caused by human papillomavirus (HPV) types 6 and 11. Denmark has provided the quadrivalent HPV vaccine to all 12-year-old girls since 2009 and catch-up vaccination to girls up to 15 years since 2008, with up to 80% to 85% vaccine coverage. We determined the incidence of GWs in Denmark since 1996, focusing on the period after licensing of HPV vaccination (October 2006). METHODS: From the Danish National Patient Register, we identified all hospitalizations and outpatient consultations for GWs between January 1995 and July 2011. Poisson regression was used to estimate average annual percentage changes. RESULTS: The overall incidence of GWs in women increased significantly until 2007, followed by an average yearly decline of 3.1% (95% confidence interval [CI], -5.5 to -0.7). In men, the incidence increased by 6.2% per year from 2004 (95% CI, 4.6-7.8). Stratifying on age, a significant decline was seen only for young women, particularly those aged 16 to 17 years, in whom GWs were virtually eliminated (average annual percentage change, -45.3%; 95% CI, -55.8 to -33.3). The incidences of genital Chlamydia, syphilis, and gonorrhea were stable or increased during the study period. CONCLUSIONS: The incidence of GWs decreased substantially among women with high HPV vaccine coverage, pointing to the effect of the national HPV vaccination program.
Assuntos
Condiloma Acuminado/epidemiologia , Condiloma Acuminado/prevenção & controle , Vacinação em Massa , Programas Nacionais de Saúde , Vacinas contra Papillomavirus/administração & dosagem , Vigilância de Evento Sentinela , Adolescente , Adulto , Distribuição por Idade , Criança , Dinamarca/epidemiologia , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-IdadeRESUMO
There are no published clinical studies evaluating the impact of warts on quality of life after transplantation. The aim of this study was to determine the frequency of self-reported skin warts and skin cancer and their impact on quality of life in kidney transplanted patients, as measured with the Dermatology Life Quality Index (DLQI). Of 740 patients with a functioning renal allograft and were free of dialysis who were surveyed, 568 returned the questionnaires. Patients were asked about general health issues, with a focus on transplantation history, cutaneous warts and whether they had ever had cutaneous cancer. A total of 285 (52%) patients replied that they had warts, and these increased with time since last transplantation, with a p-value < 0.0001. A total of 101 patients (18%) reported that they had ever had skin cancer. The median DLQI was 0 for patients not having warts, 1 for patients with warts, and 2 for patients having warts and skin cancer. In conclusion, renal transplant recipients experience increasing numbers of warts and skin cancer over time, and having skin cancer impairs patients' quality of life to a greater degree than warts.
Assuntos
Transplante de Rim/psicologia , Qualidade de Vida , Neoplasias Cutâneas/psicologia , Verrugas/psicologia , Adulto , Idoso , Efeitos Psicossociais da Doença , Dinamarca/epidemiologia , Feminino , Nível de Saúde , Humanos , Incidência , Transplante de Rim/efeitos adversos , Transplante de Rim/imunologia , Modelos Lineares , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Neoplasias Cutâneas/epidemiologia , Neoplasias Cutâneas/imunologia , Inquéritos e Questionários , Fatores de Tempo , Verrugas/epidemiologia , Verrugas/imunologiaRESUMO
Omalizumab is a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of IgE. Omalizumab has been approved for the treatment of moderate to severe asthma; however, there is currently more and more data showing promising results in the management also of chronic urticaria. We present a case series of 19 patients with chronic urticaria treated in a university department with omalizumab and give an overview of the existing literature comprising an additional 59 cases as well as a total of 139 patients enrolled in two randomized controlled trials comparing omalizumab with placebo. The collective evidence points to omalizumab as a safe and effective treatment option for patients with chronic urticaria who do not sufficiently respond to standard therapy as recommended by existing guidelines.
RESUMO
Syphilis is still a serious disease with diagnostic difficulties. In the present clinical case a patient had a routine serology screen for syphilis and HIV at a venerology clinic. He had previously presented with anogenital tumors, but the diagnosis was uncertain. A polymerase chain reaction (PCR) analysis was performed in addition to serology, and the diagnosis of syphilis in the secondary stage was confirmed. This case demonstrates how PCR technology can assist in the diagnosis of syphilis at early stages and underlines the importance of syphilis screening in homosexual men presenting with anogenital complaints.
Assuntos
Condiloma Acuminado , Sorodiagnóstico da Sífilis , Sífilis/diagnóstico , Adulto , Canal Anal/patologia , Condiloma Acuminado/diagnóstico , Condiloma Acuminado/patologia , Diagnóstico Diferencial , Homossexualidade Masculina , Humanos , Masculino , Papillomaviridae/genética , Reação em Cadeia da Polimerase , Sífilis/tratamento farmacológico , Sífilis/patologia , Treponema pallidum/genéticaRESUMO
Diagnosing gonorrhoea from extra-genital as well as genital sites is important in managing this sexually transmitted disease. In this study we evaluated a screening procedure for Neisseria gonorrhoeae (GC) from all sample sites in a low-prevalence setting. A total of 69,252 specimens submitted for Chlamydia trachomatis testing were also examined for GC on the BD Viper™ platform using the BD Probetec ET system. In order to avoid false-positive results all GC BD reactive samples were re-tested using a PCR method with the porA pseudogene as target. Using this method we screened 170% more samples for GC than in the previous year, in the same population, and diagnosed more than twice as many GC-positive episodes. The BD system can be used successfully to screen extra-genital as well as genital specimen types for GC in a low-prevalence area if it is combined with a validated confirmatory PCR test.